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The hepatitis B virus posttranscriptional regulatory element (PRE) is an RNA cis-element that is required for high-level
expression of viral surface gene transcripts and appears to function by activating mRNA export to the cytoplasm. We have
previously shown that multiple fragments of the PRE bind to two cellular proteins of approximately 35 and 55 kDa in molecular
mass and that this binding correlates with function. By a combination of column chromatographic techniques and SDS-
polyacrylamide gel electrophoresis, we have been able to purify the smaller protein. Amino-terminal sequencing of the
purified protein shows identity to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an RNA-binding glycolytic enzyme
that has been implicated in the export of tRNA. Immunoprecipitation analysis reveals that GAPDH is indeed present in the
protein-RNA complex resulting from incubation of crude nuclear extracts with a functional region of the PRE. Furthermore,
binding of the cellular 35 kDa protein to the PRE fragment is blocked by NAPDH, as would be expected for RNA binding by
GAPDH. Finally, purified commercial GAPDH also binds specifically to this RNA fragment. Therefore, GAPDH is one of the
cellular proteins that binds to the PRE, and may be involved in the posttranscriptional regulation of hepatitis B virus gene
expression. © 1998 Academic Press
INTRODUCTION
Hepatitis B virus (HBV) is a small DNA virus that is a
major cause of chronic hepatitis, cirrhosis, and hepatocel-
lular carcinoma worldwide (Hollinger, 1996). HBV contains
a 3.2-kb circular DNA genome and undergoes reverse
transcription during its replication cycle (Ganem, 1996).
There are four major promoters, all on the same strand,
which give rise to unspliced transcripts that are translated
into at least seven primary protein products (Yen, 1993).
Most studies on HBV gene expression have focused on
DNA sequences that regulate transcriptional initiation.
However, recently we and others have identified a region of
the HBV S transcripts, the posttranscriptional regulatory
element (PRE), that is required for the high-level expression
of these transcripts (Huang and Liang, 1993; Huang and
Yen, 1993, 1994; Donello et al., 1996; Yen, 1998). This cis-
acting RNA element does not increase the rate of transcrip-
tion from the S promoter. Rather, it acts posttranscriptionally
to increase the amount of S transcripts in the cytoplasm
without increasing their stability (Huang and Liang, 1993;
Huang and Yen, 1994). Therefore, the PRE appears to allow
the efficient export of the S transcripts from the nucleus to
the cytoplasm. An intron from the b-globin gene can func-
tionally substitute for the PRE, and conversely the PRE can
substitute for an intron in allowing high-level expression of
the b-globin cDNA (Huang and Yen, 1995). Since the S
transcripts are intronless, these data suggest that the PRE
functions to bypass an intron-requiring pathway of mRNA
export from the nucleus. Alternatively, it has been sug-
gested that the HBV S transcripts may contain cryptic splice
sites that result in dead-end complex formation with spli-
ceosomes and that the PRE functions to rescue S tran-
scripts from these complexes and hence allow their escape
from the nucleus (Huang and Liang, 1993). Current data do
not allow a clear discrimination between these possibili-
ties, which are not mutually exclusive.
In a continuing effort to understand the mode of action
of the PRE, we are characterizing the cellular proteins
that interact with the PRE. These proteins must be im-
portant for the function of the PRE because no viral
proteins are needed for PRE activity, and their identifica-
tion may clarify the precise role of the PRE in HBV mRNA
export. We have previously shown that the PRE com-
prises several fragments, each of which shows little
activity in an RNA export assay, but which shows activity
when multimerized (Huang et al., 1996). We have also
shown that each active fragment binds specifically to two
cellular proteins, approximately 35 and 55 kDa in molec-
ular mass, which we named PRE-interacting protein (PIP)
1 and 2, respectively (Huang et al., 1996, 1998). In this
report, we present several lines of data, showing that
PIP-1 is glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), an RNA-binding glycolytic enzyme that has
1 To whom correspondence should be addressed at: Pathology 113B,
4150 Clement St., San Francisco, CA, 94121. Fax: (415) 750-6947; E-mail:
yen.ti@sanfrancisco.va.gov.
VIROLOGY 248, 46–52 (1998)
ARTICLE NO. VY989255
0042-6822/98 $25.00
Copyright © 1998 by Academic Press
All rights of reproduction in any form reserved.
46
been implicated in the export of tRNA out of the nucleus
(Singh and Green, 1993). Therefore, GAPDH may play a
hitherto unsuspected role in mRNA export, as well.
RESULTS
Purification and partial sequencing of PIP-1
Previously, we demonstrated that the central fragment of
the PRE (fragment III) binds most strongly to PIP-1 and
PIP-2 (Huang et al., 1996). Therefore, to follow PRE-binding
activity during purification, we used 32P-labeled fragment III
as a probe in gel-shift assays. Total COS cell extracts,
shown by preliminary experiments to be a rich source of
PIPs (data not shown) were applied to a DEAE cellulose
column and eluted with a salt gradient. The PRE-binding
fraction was found in the flow-through fraction. This fraction
was then applied to a Bio-Rex 70 column and eluted with a
salt gradient. The 0.2 M NaCl eluate contained the PRE-
binding activity (Fig. 1A). This fraction was electrophoresed
on a SDS-polyacrylamide gel and found to comprise rela-
tively few protein species (Fig. 1B, lane CB). A major spe-
cies migrated at ;35 kDa and thus was a candidate PIP-1.
This tentative identification was supported by Northwestern
blotting, which revealed the 35 kDa protein to be the only
protein in the fraction that bound to fragment III (Fig. 1B,
lane NW). Preparative SDS-polyacrylamide gel electro-
phoresis was performed on the Bio-Rex fraction, and the
separated proteins blotted onto a PVDF membrane. The
PIP-1 band was localized by staining with amido black,
excised, and subjected to N-terminal sequencing. The re-
sulting sequence is shown in Fig. 2. A database search
revealed exact identity with the N-terminus of human
GAPDH (Fig. 2). GAPDH is a homotetrameric protein, with
334 amino acid residues and a calculated molecular mass
of 36.85 kDa per monomer, compatible with that of PIP-1.
Binding of commercial GAPDH to PRE
GAPDH is well known to catalyze the oxidation of
glyceraldehyde-3-phosphate to 3-phosphoglyceroyl phos-
phate, using NAD as a cofactor. Therefore, the identifi-
cation of GAPDH as PIP-1 is somewhat surprising. How-
ever, its dinucleotide-binding domain (the so-called
Rossman fold) is also known to mediate specific binding
to certain RNA species (Nagy and Rigby, 1995). To con-
firm that GAPDH binds to the PRE and in particular to
fragment III, we performed gel-shift analysis with com-
mercial rabbit GAPDH purchased from Sigma. Figure 3A
shows that a major shifted band was formed, in a con-
centration-dependent manner, when labeled fragment III
was used as the probe (lanes 4 and 5). This shifted band
co-migrated with the major shifted band formed by puri-
fied PIP-1 and fragment III (Fig. 3A, lane 3), but migrated
slightly faster and tighter than the shifted band formed by
nuclear extracts, presumably reflecting the presence of
PIP-2 and perhaps other cellular factors in nuclear ex-
tracts. A weaker, slower migrating band was also formed
when fragment III was incubated with either PIP-1 or
commercial GAPDH (Fig. 3A). The significance of this
band is unclear, but it may represent the binding of a
second molecule of GAPDH to fragment III. The binding
of GAPDH to fragment III is specific because no shifted
FIG. 1. (A) EMSA of purified PIP-1, using approximately 0.14 mg of total
protein, and 32P-labeled fragment III of PRE. Competitor is unlabeled
fragment III. SB, shifted band; FP, free probe. (B) Coomassie Blue
staining of purified PIP-1 (lane marked CB), and Northwestern blotting
of a parallel lane with 32P-labeled fragment III.
FIG. 2. N-terminal sequences of PIP-1 and human GAPDH.
FIG. 3. (A) EMSA of 32P-labeled fragment III in the presence of total
HuH-7 nuclear extracts (;5.4 mg total protein/20 ml), PIP-1 (;1.4 mg/ml,
corresponding to ;200 nM GAPDH), or GAPDH at the indicated con-
centrations. SB, shifted band; FP, free probe. (B) EMSA of 32P-labeled
5S rRNA in the presence of indicated concentrations of GAPDH.
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band was formed when labeled 5S rRNA was used as
the probe, even at GAPDH concentration as high as 1300
nM (Fig. 3B). In addition, when labeled fragment III was
used as a probe in either Northwestern blotting of com-
mercial GAPDH or UV-cross-linking to GAPDH, a protein
of the appropriate size became labeled (Fig. 4A and 4B,
respectively). Therefore, the RNA binding activity in com-
mercial GAPDH is unlikely to have been the result of a
minor contaminating protein.
NAD and NADH compete for the binding of GAPDH to
several RNA species because the dinucleotide-binding
domain mediates the binding of GAPDH to RNA (Nagy
and Rigby, 1995, Schultz, et al., 1996). To determine
whether this is also the case with GAPDH binding to the
PRE, we performed UV-cross-linking of GAPDH to la-
beled fragment III in the presence of increasing concen-
trations of NADH. Figure 4B shows that NADH indeed
prevents this interaction in a concentration-dependent
manner (lanes 2 to 5). Furthermore, NADH also inhibits
the binding of PIP-1 in crude nuclear extracts to fragment
III (Fig. 4B, lanes 7 to 10), consistent with the identifica-
tion of PIP-1 as GAPDH. However, less NADH is needed
to prevent the binding of PIP-1 in crude nuclear extracts
(lane 10 contains 100 mM NADH, as compared with 14
mM in lane 5). The reason for this discrepancy is unclear,
but is likely due to the presence of endogenous NADH in
the extracts. Interestingly, the binding of PIP-2 to frag-
ment III is likewise inhibited by NADH (Fig. 4B, lanes 7 to
10), raising the possibility that PIP-2 may also contain the
dinucleotide-binding domain that mediates RNA binding
by GAPDH. Alternatively, it is possible that GAPDH en-
hances the binding of PIP-2 to RNA.
Presence of GAPDH in nucleus and in complex of
fragment III with nuclear proteins
PIP-1 is present in nuclear extracts (Fig. 4B). Yet,
GAPDH is usually thought of as a cytosolic protein be-
cause it has an important function in glycolysis. How-
ever, it has also been reported to be present in the
nucleus by conventional immunofluorescence (Singh
and Green, 1993, Sioud and Jespersen, 1996, Sirover,
1997). To confirm that GAPDH is present in the nuclei of
the cells that we use, we performed immunostaining for
GAPDH followed by confocal microscopy. Indeed, a sig-
nificant amount of GAPDH is present within the nuclei of
both COS (monkey kidney) and HuH-7 (human hepa-
toma) cells (Fig. 5), although the relative amount of nu-
clear GAPDH shows considerable cell-to-cell variation.
Finally, to confirm that GAPDH is actually present in
the complex that is formed by the binding of the PRE to
nuclear proteins, nuclear extracts UV-cross–linked to
32P-labeled fragment III were immunoprecipitated with a
monoclonal antibody to GAPDH. As shown in Fig. 6, this
antibody was able to precipitate the labeled PIP-1 band,
which co-migrated with commercial GAPDH cross-linked
to fragment III (lanes 1 and 3, respectively). In contrast, a
monoclonal antibody to Rev was not able to precipitate
this band (lane 2), thus confirming the specificity of the
immunoprecipitation.
DISCUSSION
The HBV PRE increases HBV gene expression at the
posttranscriptional level, probably by increasing RNA
export out of the nucleus. Previously, we have found two
cellular proteins that bind to the PRE (Huang et al., 1996).
By a combination of standard protein purification tech-
niques, we have purified the smaller protein (PIP-1) and
determined that its N-terminal sequence is identical to
that of GAPDH. The molecular masses of PIP-1 and
GAPDH monomer are also similar. Pure commercial
GAPDH binds to the PRE but not to 5S rRNA, and GAPDH
is present in the cellular protein mixture that is bound by
the PRE, as revealed by immunoprecipitation by com-
mercial antibodies to GAPDH. Therefore, GAPDH is a
bona fide PRE-binding protein that appears to be identi-
cal to PIP-1. Indeed, we have previously shown that
EMSA that cytosolic extracts contain a PRE-binding ac-
tivity (Fig. 4B in Huang et al., 1996), but had deemed it
FIG. 4. (A) Northwestern blotting of commercial rabbit GAPDH (7.5 mg), using 32P-labeled fragment III as the probe. (B) UV-cross-linking of
32P-labeled fragment III to either 1 mg of commerical rabbit GAPDH (lanes 1 to 5) or ;5.4 mg of total HuH-7 nuclear extracts (lanes 6 to 10), in the
presence of increasing concentrations of NADH. Lanes 2 to 5 contain 14 mM, 140 mM, 1.4 mM, and 14 mM NADH, respectively, while lanes 7 to 10
contain 0.1, 1, 10, and 100 mM NADH, respectively.
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‘‘non-specific’’ because the binding was competed by
tRNA. Because GAPDH is known to bind tRNA (Singh
and Green, 1993), it appears that we had actually de-
tected the binding of cytosolic GAPDH to the PRE.
Our discovery that GAPDH binds specifically to the
PRE is at first glance surprising, but several groups of
researchers have previously found that GAPDH binds
specifically to RNA from diverse sources, including hep-
atitis A virus 59-untranslated RNA, parainfluenza virus
39-genomic RNA, AU-rich elements in the 39-untranslated
region of several cellular genes, and tRNA (Singh and
Green, 1993; Nagy and Rigby, 1995; De et al., 1996;
McGowan and Pekala, 1996; Schultz et al., 1996). Fur-
thermore, other enzymes with dinucleotide-binding do-
mains also show specific RNA binding (Hentze, 1994).
These include thymidylate synthase, dihydrofolate reduc-
tase, and isocitrate dehydrogenase (Chu et al., 1991,
1993; Elzinga et al., 1993), which bind to mRNAs and may
be involved in regulating their translation, and glutamate
dehydrogenase, which binds to guide RNA in the para-
site Leishmania tarentolae (Bringaud et al., 1997). As a
result, it has been suggested that dinucleotide-binding
enzymes play important roles in linking cellular metabo-
lism to control of gene expression at the post-transcrip-
tional level (Hentze, 1994). Thus, a role of GAPDH in the
metabolism of HBV mRNAs would not be unprecedented.
On the other hand, the functional significance, if any, of
the specific binding of GAPDH to RNA has not been
clearly established. There is circumstantial evidence that
GAPDH may act as a negative regulator of translational
of hepatitis A virus (Schultz et al., 1996). While GAPDH
binds in vitro to AU-rich elements clearly implicated in
controlling mRNA stability (Nagy and Rigby, 1995;
McGowan and Pekala, 1996), there is no direct evidence
that GAPDH can modulate the stability of these tran-
scripts in vivo. Interestingly, though, a role for GAPDH in
the export of tRNA out of the nucleus has been sug-
gested because a tRNA mutant that does not bind to
GAPDH is retained in the nucleus (Singh and Green,
1993). It is not clear if this role is direct or indirect.
It should be pointed out that multiple isoforms of GAPDH
have been described in many organisms (Karpel and Bur-
chard, 1981; Jedziniak et al., 1986; Nickells and Browder,
1988; Soukri et al., 1996). The molecular basis of these
different forms has not been defined, but it is possible that
posttranslational modification is involved. Alternatively,
there may even be different primary forms of GAPDH trans-
lated from distinct mRNAs because numerous apparent
FIG. 5. Confocal fluorescence microscopy of HuH-7 and COS cells (A and B, respectively), with propidium iodide staining for DNA (left) and
simultaneous antibody staining for GAPDH (right). One cell in each panel (arrow) shows nuclear staining for GAPDH. Each panel shown is from near
the middle of these two nuclei (at least 2 mm from the top and bottom).
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GAPDH-related pseudogenes have been identified in the
human genome (Ercolani et al., 1988). Thus, it is certainly
possible that the form of GAPDH that binds RNA in vivo may
be different from the major form that performs glycolytic
functions. Indeed, while Saccharomyces cerevesiae codes
for multiple isoforms of GAPDH from three distinct genes
(McAlister and Holland, 1985), only the most basic isoform
of yeast GAPDH is capable of melting RNA (Karpel and
Burchard, 1981).
In conclusion, we have presented evidence that
GAPDH binds specifically to the HBV PRE. While the
functional significance of this interaction is as yet un-
known, the fact that GAPDH has now been implicated in
the export of two unrelated RNA species is provocative,
and additional studies to determine the functional signif-
icance of this interaction must be performed.
EXPERIMENTAL PROCEDURES
Plasmids and in vitro transcription
A DNA fragment comprising fragment III of HBV PRE
was inserted into the SmaI site of plasmid pGEM7 (Pro-
mega), such that the sense RNA would be transcribed
from the T7 promoter (Huang et al., 1996). Plasmid pXlo
containing Xenopus oocyte 5S rRNA gene under the
control of a T7 promoter was a kind gift from Dr. Roma-
niuk (Romaniuk et al., 1987). For in vitro transcription of
RNA, pXlo was linearized by digestion with DraI, while
the other plasmids were linearized by digestion with
HindIII. All linearized plasmids were transcribed by T7
RNA polymerase and then digested with RNase-free
DNase, using the protocol supplied by the manufacturer
(Promega). For the synthesis of labeled RNA, the tran-
scription reactions were performed in the presence of 80
mCi of [32P]-UTP (3000 Ci/mmol, from New England Nu-
clear).
Purification of PIP-1
COS cells were grown at 37°C in Dulbecco’s modified
Eagle’s medium H21 with 10% fetal bovine serum under
an atmosphere of 93% air/7% CO2. The cells (4 3 10
7)
were washed in 4 ml of phosphate-buffered saline (PBS)
twice, released from the plates by trypsinization, resus-
pended in 2 ml of buffer containing 15 mM HEPES (pH
7.8), 10% glycerol, 0.1 mM EDTA, 1 mM DTT, 10 mM
Na2S2O5, 1 mM pepstatin, 1 mM aprotinin and 1 mM
PMSF, and sonicated 10 times at 4°C (1 s each with 5-s
cooling intervals). The sonicate was centrifuged at
15,000 rpm in a Sorvall RC5B centrifuge for 15 min at 4°C,
and the supernatant was applied to a 5 ml DEAE cellu-
lose column preequilibrated with 10 volumes of buffer A
(15 mM HEPES, pH 7.8, 10% glycerol, 1mM DTT and 0.1
mM PMSF). The column was washed with 10 ml of buffer
A, and the bound proteins were eluted with a linear 0.1 to
2.0 M gradient of NaCl in buffer A (20 ml total). Each
fraction was assayed for PIP activity by the electro-
phoretic mobility shift assay (EMSA; see below). The
fractions with PIP activity were pooled and dialyzed
against buffer A at 4°C overnight. The dialysate was then
applied to a 3 ml Bio-Rex 70 column preequilibrated in
buffer A. The column was washed with the same buffer
and eluted with a linear gradient of 0 to 1.6 M NaCl in
buffer A. The fractions containing PIP activity were iden-
tified with EMSA, pooled and stored at 220°C.
Nuclear extracts were prepared from HuH-7 cells us-
ing the method of Osborn et al. (1989).
Electrophoretic mobility shift assay, UV-cross-linking
and Northwestern blotting
RNA EMSA and UV-cross-linking were performed as
described previously (Huang et al., 1996). Northwestern
blotting to detect RNA binding by proteins separated with
electrophoresis was carried out as described by McCor-
mack et al. (1992). Briefly, 15 ml of HuH-7 nuclear extracts
was electrophoresed on a 10–20% gradient polyacryl-
amide gel in SDS-Tricine (Novex Corporation), and trans-
ferred onto a polyvinylidene difluoride membrane (Immo-
FIG. 6. Immunoprecipitation of PIP-1 by antibodies to GAPDH. Cel-
lular proteins that bind to fragment III were labeled by UV-cross-linking,
immunoprecipitated with monoclonal antibodies to GAPDH (lane 1) or
to HIV-1 Rev (lane 2), and then separated by SDS-polyacrylamide gel
electrophoresis and detected by autoradiography. A major band at ;45
kDa was precipitated by anti-GAPDH but not by anti-Rev. This band
co-migrated with commercial GAPDH UV-cross–linked to fragment III
(lane 3), and migrates slightly slower than expected, presumably be-
cause of the covalently crosslinked RNA (in this experiment, RNase
was not used to remove excess RNA, because of the prolonged
incubation needed for immunoprecipitation). The higher molecular
weight material probably represents GAPDH multimers linked by RNA
because native GAPDH is a homotetramer.
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bilon-P, Millipore Corp.) at 20 V, 4°C overnight, in a buffer
containing 24 mM Tris, 190 mM glycine, and 20% meth-
anol. The membrane was pretreated at room tempera-
ture for 5 h in a buffer containing 50 mM HEPES, pH 7.5,
50 mM KCl, 0.05% Triton X-100, 0.04% ficoll, 0.04% poly-
vinyl pyrollidone, 0.08% bovine serum albumin, 2.5 mM
EDTA, and 7.5 mg/ml poly-G. The membrane was then
incubated in 20 ml of the same buffer containing 2 3 106
cpm of labeled RNA, washed four times (15 min each) in
buffer without RNA, and exposed to film for autoradiog-
raphy.
Amino-terminal sequence analysis
Partially purified PIP-1 was electrophoresed on a 16%
SDS-polyacrylamide gel, and electrotransfered to a poly-
vinylidene difluoride membrane (Immobilon-P, Millipore
Corp.) in 10 mM 3-[cyclohexylamino]-1-propanesulfonic
acid, 10% methanol, pH 11.0 at 4°C, 90 volts, for 1 h.
Protein bands were visualized by amido black staining.
The band migrating at ;35 kDa (approximately 0.5 mg)
was excised for amino-terminal sequencing on a 494
Procise protein sequencer (Perkin–Elmer, Applied Bio-
systems Division, Foster City, CA).
Immunoprecipitation following UV-cross-linking
UV-cross-linking was performed as previously de-
scribed (Huang et al., 1996), except that RNase digestion
was not performed after the cross-linking reaction, to
prevent total digestion of the RNA during the antibody
incubations. To 20 ml of this reaction mixture, 580 ml of
RIPA buffer (Harlow and Lane, 1988) containing 1% Triton
X-100 and 33 mg/ml of bovine serum albumin was added.
The mixture was then incubated with 10 ml of monoclonal
antibody against GAPDH (1 mg/ml, from Advanced Im-
munochemical) at 4°C for 1 h. One hundred microliters of
a 20% suspension of freshly washed protein G-Sepha-
rose beads (Sigma Corp.) equilibrated in RIPA buffer was
added to each reaction and then mixed continuously at
4°C for 1 h. The beads were pelleted in a microcentri-
fuge, washed five times with RIPA buffer, and then placed
into 50 ml of SDS sample buffer. After being heated at
100°C for 4 min, the beads were pelleted in the micro-
centrifuge, and 40 ml of the supernatant was electropho-
resed on a SDS-polyacrylamide gel. As a negative con-
trol, a monoclonal antibody against human immunodefi-
ciency virus I Rev protein (Intracel) was used.
Immunofluorescence confocal microscopy
HuH-7 and COS cells grown on two-well chamber
slides (LabTek) were washed with PBS and fixed with
methanol for 10 min at room temperature. After two
washes with PBS, the cells were treated with 10 mg/ml of
DNase-free RNase for 1 h at 37°C. Then the cells were
incubated for 40 min at 37°C with the monoclonal murine
antibody against rabbit GAPDH (1 mg/ml, from Advanced
Immunochemicals Inc.), diluted 1:100 in PBS with
DNase-free RNase. After extensive washing in PBS, the
cells were incubated for 40 min at 37°C with fluorescein
isothiocyanate-labeled goat anti-mouse immunoglobu-
lins (Sigma), diluted 1:50 in PBS with 20 mg/ml of pro-
pidium iodide. As a negative control, cells were treated
identically, except that the primary antibody was omitted.
Confocal images were collected on a Zeiss Laser-
Scanning Microscope with a Zeiss 363 Plan Apo oil-
immersion objective. Excitation was set at the 488 nm
line of an argon ion laser. Epifluorescence emission was
split into two detectors by a 560-nm dichroic mirror.
Fluorescein emission was detected using a 530 6 30 nm
bandpass filter, while propidium iodide emission was
detected using a 620-nm longpass filter.
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